Leqvio (inclisiran) - Novartis
Jardiance (empagliflozin) - Eli Lilly, Boehringer Ingelheim
Magnetic Particle Imaging of Macrophage Phagocytosis Evaluates Plaque Vulnerability and Therapeutic Efficacy in Atherosclerosis. (PubMed, Arterioscler Thromb Vasc Biol) - Oct 16, 2026 - "After 10-week treatment with a proprotein convertase subtilisin/kexin type 9 inhibitor (inclisiran) or a sodium-glucose cotransporter-2 inhibitor (empagliflozin), macrophage phagocytosis and plaque vulnerability were assessed by PESPION-enhanced MPI and histopathology, respectively. MSR1 is a phagocytosis-related molecule associated with plaque vulnerability. PESPION-enhanced MPI provides a sensitive, noninvasive tool for quantifying MSR1-mediated macrophage phagocytosis, enabling robust evaluation of plaque vulnerability and pharmacological response." 
Journal • Atherosclerosis • Cardiovascular • APOE
http://www.ncbi.nlm.nih.gov/pubmed/42877977
 
Hui Hui; Jie Tian; Lei Gao; Rundu Chen; Wei Tong; Ying Han; Yundai Chen; Yuxing Chen
 
Oct 16, 2026
 
Prev Next